A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme‐inducing drugs.

British Journal of Clinical Pharmacology

Volumn 10, Issue 5, 1980, Pages 491-497

  Perucca, E ^a   Hedges, A ^a   Makki, KA ^a   Richens, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LIDOCAINE; PHENAZONE;

CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INDUCTION; EPILEPSY; HUMAN CELL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; THERAPY;

ADOLESCENT; ADULT; ANTICONVULSANTS; ANTIPYRINE; BIOLOGICAL AVAILABILITY; ENZYME INDUCTION; GLUCARIC ACID; HUMANS; KINETICS; LIDOCAINE; MIDDLE AGED;

EID: 0019169908     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1980.tb01794.x     Document Type: Article

References (46)

1. Effect of pentobarbital on the disposition of alprenolol
2. Comparison of plasma levels of antipyrine, tolbutamide and warfarin after oral and intravenous administration
3. Lignocaine pharmacokinetics in man: dose and time studies
4. Lignocaine disposition kinetics in monkey and man: I prediction by a perfusion model
5. Oral absorption and disposition kinetics of lignocaine hydrochloride in dogs
6. Pharmacokinetics of lignocaine in man
7. The reduction of lignocaine clearance by dl‐propranolol: an example of hemodynamic drug interaction
8. Clinical implications of enzyme‐induction
9. Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine
10. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3‐methyl‐cholanthrene treatment
11. Inter‐individual differences in rate of drug oxidation in man
12. Lignocaine metabolism in normal and phenobarbital pretreated dogs
13. Influence of bed rest on the pharmacokinetics of phenazone
14. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes
15. Disposition of aminopyrine, antipyrine, diazepam and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination
16. Plasma lignocaine levels in patients treated with potential inducers of microsomal enzymes
17. On the metabolism of lignocaine: ii The biotransformation of lignocaine
18. Bioavailability of lignocaine in normal volunteers and cirrhotic patients
19. Comparative drug elimination capacity in man—glutethimide, amobarbital, antipyrine and sulfinpyrazone
20. Comparative metabolism of benzo(a)pyrene and drugs in human liver
21. The tissue distribution, metabolism and excretion of lignocaine in rats, guinea‐pigs, dogs and man
22. Gas‐chromatographic assessment of the reproducibility of phenazone plasma half‐life in young healthy volunteers
23. Metabolism of d‐glucuronolactone in mammalian systems. Identification of d‐glucaric acid as a normal constituent of urine
24. The relation between cytochrome P‐450 in liver biopsies and drug metabolism in patients with liver disease and in morphine addiction
25. Effect of age and sex on human drug metabolism
26. Interactions of benzodiazepines with warfarin
27. Effect of charcoal‐broiled beef on phenacetin metabolism in man
28. Clearance and biologic half‐life as indices of intrinsic hepatic metabolism
29. Clinical consequences of microsomal enzyme‐induction by antiepileptic drugs
30. The comparative enzyme‐inducing properties of antiepileptic drugs
31. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs
32. Reduction of oral bioavailability of lignocaine by induction of first‐pass metabolism in epileptic patients
33. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulphaphenazole
34. Prediction of hepatic extraction ratio from in vitro measurements of intrinsic clearance
35. Influence of route of administration on drug availability
36. Relationship between in vivo and in vitro drug metabolism in man
37. Interrelationship of hepatic blood flow, cardiac output, and blood levels of lignocaine in man
38. Factors influencing antipyrine elimination
39. Identification of glycine xylidide in patients treated with intravenous lignocaine
40. The antipyrine test in clinical pharmacology: conceptions and misconceptions
41. Genetic control of dicoumarol levels in man
42. Studies on the disposition of antipyrine, aminopyrine and phenacetin in normal human volunteers utilizing plasma, saliva and urine
43. Genetic control of drug levels and of the induction of drug‐metabolizing enzymes in man: Individual variability in the extent of allopurinol and nortriptyline inhibition of drug metabolism
44. A physiological approach to hepatic drug clearance